

openheart Treatment choices in elderly patients with ST: elevation myocardial infarction – insights from the Vital Heart Response registry

Olga Toleva,¹ Quazi Ibrahim,¹ Neil Brass,² Sunil Sookram,¹ Robert Welsh^{1,3}

To cite: Toleva O, Ibrahim Q, Brass N, *et al.* Treatment choices in elderly patients with ST: elevation myocardial infarction—insights from the Vital Heart Response registry. *Open Heart* 2015;**2**:e000235. doi:10.1136/openhrt-2014-000235

Received 27 December 2014
Revised 12 May 2015
Accepted 3 June 2015

ABSTRACT

Background: Management of elderly patients with ST elevation myocardial infarction (STEMI) is challenging and they are under-represented in trials. Accordingly, we analysed reperfusion strategies and their effectiveness in patients with STEMI ≥ 75 years compared to < 75 years within a comprehensive inclusive registry.

Methods: Consecutive patients with STEMI admitted to hospital and tracked within a regional registry (2006–2011) were analysed comparing reperfusion strategy (primary percutaneous coronary intervention (PPCI), fibrinolysis and no reperfusion) between patients ≥ 75 vs < 75 years old as well as across the reperfusion strategies in those ≥ 75 years.

Results: There were 3588 patients with STEMI with 646 (18%) ≥ 75 years old. Elderly patients were more likely female (46.9% vs 18.4%) and had more prior: angina (28.2% vs 17.2%), myocardial infarction (MI; 22.8% vs 13.9%), hypertension (67.6% vs 44.2%), heart failure (2.3% vs 0.3%) and atrial fibrillation (2.2% vs 0.5%) (all $p < 0.001$). The reperfusion strategy for patients ≥ 75 vs < 75 : PPCI 45.3% vs 41.2%, fibrinolysis 24.8% vs 45.7%, and no reperfusion 29.9% vs 13.1% ($p < 0.001$). Time from symptoms to first medical contact (median, 93 vs 78 min $p = 0.008$) and PPCI (median, 166 vs 136 min ($p < 0.001$)) were longer for ≥ 75 years. In those ≥ 75 years outcomes by reperfusion (PPCI, fibrinolysis and none) were: in-hospital death 13.3%, 9.4% and 19.7% ($p = 0.018$), and composite of death, recurrent-MI, cardiogenic shock and congestive heart failure 28%, 20% and 33.2% ($p = 0.022$).

Conclusions: Elderly patients have more comorbidities, worst in-hospital clinical outcomes and are less likely to receive reperfusion. Acknowledging physician selection of the reperfusion strategy; outcomes appear favourable in the elderly receiving fibrinolysis.

BACKGROUND

The demographic shift with increasingly ageing population, results in higher incidence of elderly patients presenting with acute coronary syndromes (ACS). Significant

KEY MESSAGES

What is already known about this subject?

▶ Timely reperfusion therapy improves outcomes in patients with ST elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention (PCI) is the dominant reperfusion strategy if it can be delivered rapidly by an experienced interventional cardiologist and team. Substantial intellectual and financial equity has been invested to develop regional STEMI networks focused on optimising patient outcomes.

What does this study add?

▶ This study adds information regarding reperfusion strategies and outcomes elderly patients with STEMI from a ‘real world’ perspective. To date there is limited randomised controlled trial data specific to elderly patients with STEMI and limited ‘real world’ data address this issue.

How might this impact on clinical practice?

▶ Our study demonstrates that one of three of elderly patients receive no reperfusion and that although primary PCI is the preferred reperfusion strategy that outcomes with fibrinolysis in this population are excellent. This data provides impetus to optimise reperfusion in this very high-risk population and identifies that the selective use of fibrinolysis can achieve excellent outcomes.



¹University of Alberta, Edmonton, Alberta, Canada

²Royal Alexandra Hospital and CK Hui Heart Centre, Edmonton, Alberta, Canada

³Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada

Correspondence to

Dr Robert Welsh;
Robert.Welsh@
albertahealthservices.ca

age-associated heterogeneity in baseline characteristics has been described to account for some of the differences in mortality from acute myocardial infarction (MI) in subgroups of elderly patients.¹ There is a gap between the evidence from ST elevation myocardial infarction (STEMI) randomised controlled trials (RCT's) and real life due to under-representation of elderly patients in these trials.² The proportion of patients eligible for reperfusion strategy decreases with advancing age and elderly patients are still less likely to receive reperfusion even if

eligible.³ Furthermore data suggests that morbidity and mortality from STEMI is higher in elderly compared to younger patients.⁴ With the existing reperfusion therapies there is still uncertainty about their use in the elderly despite evidence for mortality benefit for both fibrinolysis and primary percutaneous coronary intervention (PPCI) from RCTs and registries.^{5–7} Accordingly, we compared the baseline characteristics, reperfusion strategies and outcomes between elderly (≥ 75 years of age) and younger patients within an inclusive ‘real world registry’. Additionally, we assessed the outcomes according to the reperfusion strategy used specific to the elderly group.

METHODS

The study is a retrospective cohort analysis of the Vital Heart Response (VHR) registry which includes consecutive patients with STEMI in the period 2006 until 2011. Medical charts of all patients with an International Classification of Diseases (Ninth and 10th Revision) code for MI were reviewed to identify all patients with STEMI. Detailed data on patient demographic characteristics, mode of presentation, treatment time intervals, reperfusion therapy, in-hospital management and in-hospital events were abstracted by trained data analysts using standardised operation manuals for consistency and validity at the Epidemiology Coordinating and Research Centre at the University of Alberta (EPICORE). First medical contact (FMC) was defined using strict definition of the time of first healthcare practitioner contact documented on the patients’ chart. This included arrival of the pre-hospital paramedical personnel at the patient’s side even if prehospital diagnosis of STEMI was not obtained. For self-presenting patients, FMC was defined as the first recorded triage or registration time.

VHR is a regional reperfusion programme in Central and Northern Alberta. There are five centres in metropolitan Edmonton with two primary PCI centres. The estimated catchment area for the population is about 440 000 km² serving 1.8 million inhabitants and approximately 44% of the study population lives in a non-metropolitan region. The VHR system is activated by Emergency Medical Services from the ambulance or emergency physicians from the emergency departments, when the clinical history and 12-lead ECG are compatible with a STEMI. For prehospital patients, the 12-lead ECG is electronically transmitted to the VHR physician who confirms the diagnosis and reviews the clinical history with the on-site practitioner and then decides on one of the two reperfusion strategies in the protocol (PPCI or fibrinolysis) depending on patient’s characteristics and the estimated temporal factors. For in-hospital patients with STEMI, on-site clinicians review the patient’s characteristics and investigations and determine the reperfusion strategy with the potential to activate the VHR process of care described for prehospital patients. Practising clinicians typically follow the American College of Cardiology and American Heart Association

STEMI guidelines. The VHR registry includes all patients with STEMI that survive to hospital regardless of activation of the VHR protocol described above.

Reperfusion therapy

Reperfusion strategy is defined as the therapy within 24 h of presentation (only one of the following may be recorded for any patient): *No reperfusion therapy*—when the patient does not receive any primary reperfusion (no PPCI and no Fibrinolytic); *Fibrinolytic*—when the patient receives fibrinolytic agent as a reperfusion strategy; *PPCI*—when the patient receives cardiac catheterisation with the intent to conduct PPCI including patients who were sent for angiogram but were unable to receive stent or balloon inflation.

All patients receive a loading dose of acetylsalicylic acid (>160 mg). For the Fibrinolytic strategy: weight-adjusted tenecteplase (TNK), clopidogrel 300 mg loading dose (75 mg daily), and enoxaparin (30 mg intravenous and 1 mg/kg subcutaneous) are given. For patients ≥ 75 years the loading dose of clopidogrel and the intravenous enoxaparin are omitted, and the subcutaneous dose of enoxaparin is reduced to 0.75 mg/kg. For patients assigned to primary PCI clopidogrel 600 mg is given. Prehospital diagnosed and treated patients receive intravenous (30 mg) and subcutaneous (1 mg/kg) enoxaparin, and patients diagnosed in hospital typically receive unfractionated heparin (70 U/kg intravenous).

Study cohorts, definitions and statistical analysis

Participants in this study were divided into two groups according to age: elderly group (≥ 75 years old) and younger group (< 75 years old). For the current analysis the *Primary outcome* was defined as the composite of in-hospital death, recurrent MI (Re-MI), cardiogenic shock and congestive heart failure (CHF). *Secondary outcomes* (with definitions) included in-hospital: death of any cause, Re-MI (recurrent symptoms, ST elevation and CK elevation); Cardiogenic shock (evidence of systolic blood pressure < 90 mm Hg for at least 30 min in the presence of normal heart rate with signs of end organ hypoperfusion (cool extremities, low urine output, mental confusion), with inotropic support for more than 30 min, mechanical support with intra-aortic balloon pump (shock postcoronary artery bypass grafting (CABG) was not recorded); and CHF (newly diagnosed heart failure and at least one of the following conditions requiring treatment with diuretics: pulmonary oedema/congestion on chest X-ray, crackles greater than 1/3 of the lung fields (Killip class > 2) and dyspnoea with oxygen saturation less than 90% in the absence of known lung disease). *Safety outcomes* (with definitions) included: cerebrovascular event (CVA) with haemorrhagic stroke (CT scanning, MRI or autopsy); CVA with ischaemic stroke (lateralising neurological complications after the time of admission and prior to discharge). Major bleeding with or without blood transfusion: bleeding that causes hemodynamic compromise

requiring blood or fluid replacement, inotropic support, ventricular assist device, intra-aortic balloon pump, surgical intervention or cardiopulmonary resuscitation to maintain a sufficient cardiac output or a decrease in the haemoglobin by >30 g/L with hypotension or signs of shock. Minor bleeding: not requiring blood transfusion and not leading to a hemodynamic compromise requiring other intervention or support. Bleeding post-CABG is recorded separately.

Demographic characteristics, health risk factors, treatment choices and in-hospital clinical outcomes were compared between age ≥ 75 years and age < 75 years patients with STEMI. Means (SDs) or medians (IQRs) were reported for continuous variables. Categorical variables were presented as counts (percentages). For comparison of continuous variables between elderly and younger patients, t test or Mann–Whitney U test was used. The χ^2 or Fisher's exact test was used for categorical variables.

We examined the associations of treatment choices, demographic characteristics, and health risk factors with the composite outcome in the overall study population and in particular, elderly patient's ≥ 75 years. Exploratory data analyses were performed to detect possible association of these variables with the outcome. Multivariable logistic regression analyses were performed to see the association of clinically relevant variables with the outcome.

A multivariable regression model of the outcome was fitted with the variables that were found significant ($p < 0.20$) at the univariable analyses and were clinically important. The variables that were significant at $p < 0.05$ are kept in the model along with clinically relevant variables. Analyses were performed using statistical packages STATA V.12 and IBM SPSS Statistics V.21.

RESULTS

For patients ≥ 75 years old compared to < 75 years old

In this registry there were 646 who were ≥ 75 years old and 2942 patients who were < 75 years old. Elderly patients were more often female and had more comorbidities including: prior angina, prior MI, prior heart failure and hypertension (table 1). More elderly had a new left bundle branch block as the presenting ECG (4.4% vs 1.5%, $p < 0.001$); whereas lateral MI was seen in less proportion of the elderly compared to younger patients (23.3% vs 29.0%, $p = 0.005$). No significant differences were identified in the proportions of elderly versus young with presentation of anterior MI (45.4% vs 43.3%, $p = 0.36$); inferior MI (53% vs 55.2%, $p = 0.313$), posterior MI (6.9% vs 8.7%, $p = 0.152$) respectively. There was no significant difference in the presenting heart rate between the two groups, but more elderly patients had higher Killip class > 1 compared to younger patients (table 1). The majority of elderly patients arrived by ambulance 62% vs 39% ($p < 0.001$). Time from symptom onset to FMC and time from FMC to initiation

of reperfusion were longer in the elderly (table 1). The length of hospital stay was longer in the elderly with a median duration of 6 days vs 4 days ($p < 0.001$).

The implementation of various reperfusion strategies by 10-year age increments starting at < 50 years and ending at > 80 years showed that with increasing age there is increased use of no reperfusion therapy, decreased use of fibrinolysis and similar usage of PPCI (figure 1). PPCI was performed in 45% vs 41% ($p = 0.054$), fibrinolysis in 25% vs 46% ($p < 0.001$) and no reperfusion therapy in 30% vs 13% ($p < 0.001$) in those ≥ 75 years old and < 75 years old respectively. Intravenous glycoprotein IIb/IIIa receptor inhibitors during index hospitalisation were utilised in 26.3% and 43.8% ($p < 0.001$), respectively. In patients ≥ 75 years they were utilised during index hospitalisation in 43.8% receiving PPCI and 15.2% receiving fibrinolysis whereas in those < 75 years they were utilised in 71.7% receiving PPCI and 29.2% receiving fibrinolysis.

The in-hospital clinical events by age are shown in table 2. Elderly patients had higher in-hospital events including: the composite of death, re-MI, cardiogenic shock and CHF occurred in 27.6% vs 13.5% ($p < 0.001$) and all individual secondary outcomes (table 2). The safety outcome showed higher rates of ischaemic stroke and major bleeding requiring transfusion in the elderly, and no difference in haemorrhagic stroke between the two groups (table 2).

When looking at the outcomes by age and reperfusion strategy following became evident: In the patients ≥ 75 years old the composite outcome occurred in 33.2% of the no-reperfusion therapy group ($n = 193$), 28% of the PPCI group ($n = 293$) and 20% of the fibrinolytic group ($n = 160$) ($p = 0.022$). Death rates were 19.7% of the no reperfusion therapy group, 13.3% of the PPCI group and 9.4% of the fibrinolytic group ($p = 0.018$). In comparison in the < 75 years old group composite outcome occurred in 17.4% of the no reperfusion therapy group ($n = 386$), 15.8% of the PPCI group ($n = 1213$) and 10.3% of the fibrinolytic group ($n = 1343$) ($p < 0.001$). Death rates were 6.5% of the no reperfusion therapy group, 4.6% of the PPCI group and 2.2% of the fibrinolytic group ($p < 0.001$).

Across all three strategies in the whole cohort there was significant utilisation of invasive procedures and revascularisation during the index hospitalisation. In those receiving no reperfusion therapy 417 (72%) underwent angiography, 254 (44%) had non-urgent PCI and 35 (6%) had CABG. In those receiving fibrinolysis 348 (23.1%) had rescue PCI, 287 (19.1%) had urgent PCI, 531 (35.3%) had non-urgent PCI and 74 (4.9%) had CABG. In those undergoing primary PCI an additional 111 (7.4%) had non-urgent PCI and 29 (1.9%) had CABG.

After adjustment for multiple variables that were described in the methods section using logistic regression analysis we were able to identify the following significant predictors of the composite outcome for the

Table 1 Selected baseline and clinical characteristics at presentation, mode of transport and temporal factors for patients with STEMI in Alberta, 2006–2011

	Age ≥ 75 years (N=646)	Age <75 years (N=2942)	p Value
Age (year), mean (SD)	82.2 (5.1)	57.2 (9.7)	<0.001
Female	303 (46.9)	540 (18.4)	<0.001
Prior angina	182 (28.2)	506 (17.2)	<0.001
Previous MI	147 (22.8)	410 (13.9)	<0.001
Coronary revascularisation	80 (12.4)	335 (11.4)	0.473
Hypercholesterolemia	264 (40.9)	1269 (43.1)	0.292
Hypertension	437 (67.6)	1300 (44.2)	<0.001
Diabetes	126 (19.5)	519 (17.6)	0.264
Prior heart failure	15 (2.3)	9 (0.3)	<0.001
Atrial fibrillation	14 (2.2)	16 (0.5)	<0.001
Smoking	301 (46.6)	2233 (75.9)	<0.001
Infarct location on first diagnostic ECG			
Anterior	269 (45.4)	1137 (43.3)	0.360
Inferior	314 (53.0)	1451 (55.2)	0.313
Lateral	138 (23.3)	760 (29.0)	0.005
New LBBB	26 (4.4)	39 (1.5)	<0.001
Posterior	41 (6.9)	229 (8.7)	0.152
Heart rate (first recorded) bpm	77 (63–94)	76 (63–90)	0.109
Killip class			<0.001
I	246 (77.1)	1198 (89.1)	
II	42 (13.2)	76 (5.7)	
III	4 (1.3)	2 (0.1)	
IV	27 (8.5)	68 (5.1)	
Arrival by ambulance to first hospital	403 (62.4)	1139 (38.8)	<0.001
Time from symptom onset to FMC (min)	93 (40–240) n=499	78 (36–182) N=2546	0.008
Time from FMC to Fibrinolytic (min)	57 (39–92) n=150	51 (33–80) n=1289	0.028
Time from FMC to primary PCI (min)	166 (106–272) n=214	136 (102–208) n=991	<0.001
Length of stay in hospital (in days)	6 (4–11) n=626	4 (3–7) n=2856	<0.001

Data are presented as n (%).

FMC, first medical contact; LBBB, left bundle branch block; MI, myocardial infarction; PCI, percutaneous coronary intervention.

entire cohort: age ≥ 75 years with adjusted OR 2.11 (95% CI 1.45 to 3.07 $p < 0.001$) and Killip class >1 with adjusted OR 12.49 (95% CI 8.64 to 18.05 $p < 0.001$).

For patients ≥ 75 years old by reperfusion strategy

When we analysed the elderly group by reperfusion strategy; significant differences were demonstrated in age, Killip Class >1 and diabetes with increased

cardiovascular comorbidities in the no reperfusion therapy group (table 3).

The unadjusted in-hospital outcomes in the elderly by reperfusion strategy are shown in table 4. In hospital death and CHF were increased in the no reperfusion therapy group while resuscitated cardiac arrest occurred more often with primary PCI. Major bleeding requiring transfusion was similar in the three groups although

Figure 1 Reperfusion strategies among patients with STEMI by age in Alberta, 2006–2011. The figure represents applied reperfusion strategy by age groups (<50, 50–60, 60–70, 70–80 and ≥ 80) separated into: medical therapy without reperfusion (black \triangle), fibrinolysis (yellow \blacklozenge) and primary percutaneous coronary intervention PCI (red \square).




Table 2 In-hospital outcomes among patients with STEMI by age in Alberta, 2006–2011

	Age ≥75 years (N=646)	Age <75 years (N=2942)	p Value
Composite of Re-MI, death, cardiogenic shock and congestive heart failure (%)	178 (27.6)	397 (13.5)	<0.001
Re-MI	9 (1.4)	14 (0.5)	0.014
Death	92 (14.2)	111 (3.8)	<0.001
Cardiogenic shock	85 (13.2)	265 (9.0)	0.001
Congestive heart failure	74 (11.5)	149 (5.1)	<0.001
Cardiac arrest	86 (13.3)	320 (10.9)	0.077
Major bleed (no transfusion)	17 (2.6)	64 (2.2)	0.480
Major bleed (with transfusion)	69 (10.7)	133 (4.5)	<0.001
Non-major bleed	14 (2.2)	51 (1.7)	0.454
Cerebrovascular event			
Hemorrhage	4 (0.6)	13 (0.4)	0.528
Ischaemic	8 (1.2)	7 (0.2)	0.002

Data are presented as n (%).

Re-MI, recurrent myocardial infarction.

major bleeding without transfusion was increased with fibrinolysis. The rate of stroke was not significantly different among the three groups. The rates of haemorrhagic stroke were 0% in the no reperfusion therapy versus 0.3% in the PPCI and 1.9% in the Fibrinolytic therapy ($p=0.083$).

Across all three strategies in the elderly group there was high utilisation of invasive procedures during the index hospitalisation. In those receiving no reperfusion therapy 89 (46.1%) underwent angiography, 52 (27%) had non-urgent PCI >24 h of presentation and 6 (3%) had CABG. In those receiving fibrinolysis 134 (84%) had an angiogram, 32 (20%) had rescue PCI, 20

(12.5%) had urgent PCI <24 h of presentation, 55 (34%) had non-urgent PCI >24 h of presentation and 5 (3%) had CABG. In those undergoing primary PCI 115 (5%) had and additional non-urgent PCI and 7 (2.4%) had CABG.

In a logistic regression analysis after adjusting for the same baseline characteristics as previously described the only predictor of the composite outcome for the elderly cohort was Killip class >1 with adjusted OR 7.37 (95% CI 3.64 to 16.94). For PPCI versus no reperfusion therapy the adjusted OR was 1.05 (95% CIs 0.48 to 2.29) and for fibrinolysis versus no reperfusion therapy the adjusted OR was 0.57 (95% CIs 0.21 to 1.53).

Table 3 Baseline characteristics of patients with STEMI aged ≥75 years in Alberta, 2006–2011

	No reperfusion (n=193)	Primary PCI (n=293)	Fibrinolysis (n=160)	p Value
Age (year), median (IQR)	83 (79–87)	80 (78–84)	81 (78–86)	<0.001
Female	98 (50.8)	140 (47.8)	65 (40.6)	0.151
BMI (kg/m^2), median (IQR)	26.6 (23.2–30.5)	25.9 (23.0–28.8)	26.6 (24.0–30.7)	0.028
SBP (mm Hg), mean (SD)	136 (35)	139 (34)	134 (30)	0.371
Killip class >1	33 (35.5)	28 (18.7)	12 (15.8)	0.002
Prior angina	66 (34.2)	79 (27.0)	37 (23.1)	0.058
Previous MI	55 (28.5)	60 (20.5)	32 (20.0)	0.075
Prior coronary revascularisation	23 (11.9)	39 (13.3)	18 (11.2)	0.794
Hypercholesterolaemia	73 (37.8)	126 (43.0)	65 (40.6)	0.523
Hypertension	128 (66.3)	200 (68.3)	109 (68.1)	0.895
Diabetes	52 (26.9)	58 (19.8)	16 (10.0)	<0.001
Early CAD	19 (9.8)	28 (9.6)	14 (8.8)	0.937
Chronic treatment with Aspirin	60 (31.1)	73 (24.9)	45 (28.1)	0.324
Previous heart failure	4 (2.1)	5 (1.7)	6 (3.8)	0.394
Atrial fibrillation	4 (2.1)	6 (2.0)	4 (2.5)	0.941
Symptom onset to FMC (min), median (IQR)	115 (47–458)	92 (39–266)	85 (39–184)	0.127

Data are presented as n (%).

BMI, body mass index; CAD, coronary artery disease; FMC, first medical contact; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.

Table 4 Outcomes among patients with STEMI aged ≥ 75 years by treatments in Alberta, 2006–2011

	No reperfusion (n=193)	Primary PCI (n=293)	Fibrinolysis (n=160)	p Value
Composite of Re-MI, death, cardiogenic shock and CHF	64 (33.2)	82 (28.0)	32 (20.0)	0.022
Re-MI	1 (0.5)	5 (1.7)	3 (1.9)	0.470
Death	38 (19.7)	39 (13.3)	15 (9.4)	0.018
Cardiogenic shock	21 (10.9)	43 (14.7)	21 (13.1)	0.480
Congestive heart failure	28 (14.5)	38 (13.0)	8 (5.0)	0.011
Cardiac arrest	16 (8.3)	49 (16.7)	21 (13.1)	0.028
Major bleed (no transfusion)	1 (0.5)	8 (2.7)	8 (5.0)	0.026
Major bleed (with transfusion)	25 (13.0)	29 (9.9)	15 (9.4)	0.468
Non-major bleed	6 (3.1)	5 (1.7)	3 (1.9)	0.540
Cerebrovascular event				
Hemorrhage	0	1 (0.3)	3 (1.9)	0.083
Ischaemic	2 (1.0)	4 (1.4)	2 (1.2)	1.000

Data are presented as n (%).

CHF, congestive heart failure; PCI, percutaneous coronary intervention; Re-MI, recurrent myocardial infarction.

DISCUSSION

Our finding from this observational cohort with real life physician practices, demonstrate that elderly patients with STEMI have more comorbidities and 30% of them received no reperfusion therapy compared to 13% of the younger patients. Elderly patients had worst outcomes with a doubling of composite in-hospital events. Additionally, a gradient was demonstrated for the composite event rate and mortality by choice of reperfusion strategy. For those receiving no reperfusion therapy the composite event occurred in 33% in the elderly compared to 17% of the younger. With PPCI and fibrinolysis it was 28% and 20% in the elderly and 16% and 10% in the younger, respectively. This was similarly shown when observing in-hospital death rates in the elderly with: no reperfusion therapy 20%, PPCI 13% and fibrinolytic 9% and in the younger patients no reperfusion therapy 6.5%, PPCI 4.6% and fibrinolytic 2.2%.

These findings suggest that fibrinolytic therapy if used carefully in selected elderly patients may be beneficial and lead to reduced morbidity and mortality. These rates are different from previously published registry data analysis by Thiemann *et al*⁸ who found that the 30-day crude mortality rates in elderly who received fibrinolytic were 18% compared to 15.4% for no reperfusion therapy. In our cohort the death rates are lower overall except for the elderly group who received no reperfusion therapy. One could speculate that these elderly patients who were assigned to no reperfusion therapy most likely had contraindications to reperfusion strategy based on physicians assessment or declined such therapies. Additionally, it must be acknowledged that the VHR system of care incorporates a dual reperfusion strategy which allows the treating clinician to individualise by specific patient characteristics. Although elderly patients with STEMI have substantial increased risk compared to younger cohorts, as described in others work the application of reperfusion and evidence-based

therapy has been associated with improved outcomes over the past decade.^{9 10}

In the past there have been concerns about using reperfusion strategies in elderly patients due to the risk of bleeding, haemorrhagic CVA and contraindications to both fibrinolysis and PCI.^{8 11} The bleeding rates in our inclusive study were higher in the elderly with major bleeding occurring in 13% vs 7% in the younger patients with STEMI. The approximate doubling of bleeding in the elderly cohort is similar to other contemporary analyses although direct comparison is challenging since others limited analysis to primary PCI (transradial primary PCI in ≥ 75 years: severe bleeding 6.5% and need for transfusion 9.9%)¹² and secondary analysis of clinical trials of primary PCI.¹³ The rates of haemorrhagic stroke in the entire cohort were low and were not significantly different between the elderly and the younger patients (4 (0.6%) vs 13 (0.4%) $p=0.52$). Although ischaemic stroke occurred more frequently in the elderly (8 (1.2%) vs 7 (0.2%), $p=0.002$).

Specific to the elderly population, major bleeding requiring transfusion was similar in the three reperfusion groups, although major bleeding without transfusion was increased with fibrinolysis. Furthermore the rates of haemorrhagic stroke in the elderly were not significantly different among the three reperfusion groups, although numerically higher with fibrinolysis occurring in three patients. These safety results may be even improved further with incorporation of the half dose fibrinolytic strategy in patients >75 years as studied in the Strategic Reperfusion Early After Myocardial infarction study (STREAM).¹⁴

Finally when looking at contemporary practices it is apparent that even in those patients that did not receive acute reperfusion there was a high utilisation of invasive investigation and revascularisation. In the younger cohort 72% of the no reperfusion therapy patients had subsequent angiograms, 44% of them underwent non-

urgent PCI after 24 h of the presentation and 6% were referred to CABG, which may have played a role in the overall good outcomes in this group. Similarly in the patient's ≥ 75 -year-old group, 46% of the no reperfusion therapy patients had subsequent angiograms, 27% of them underwent non-urgent PCI after 24 h of the presentation and 3% were referred to CABG. Previously we have assessed the reason and rationale for patients with STEMI to not receive acute reperfusion from a subset of this cohort. The major reasons were: late presentation (approximately 40% of untreated), patient or family request for conservative care (approximately 23% of untreated), and planned primary PCI without an identifiable culprit lesion or failed attempted PCI (approximately 20% of untreated).¹⁵

Internationally there has been a dedicated attempt to apply mechanical reperfusion as the strategy of choice for all patients with STEMI with this being emphasised especially in the elderly patients due to their increased risk of bleeding complications from fibrinolysis. This real world contemporary analysis based on a regional reperfusion programme which has incorporated a dual reperfusion strategy with individual patient selection demonstrates excellent clinical outcomes in elderly patients with STEMI receiving fibrinolysis.

Limitations

This study is based on a comprehensive inclusive registry and is a reflection of a real life cohort and actual practices of clinicians. The observational nature of the study makes it prone to information bias. The registry is part of a dedicated quality assurance programme and only tracks patients outcomes while in hospital. Our analyses may be limited by the sample size especially relevant to the elderly group. The registry data lacks non-cardiovascular comorbidities that may influence clinician's reperfusion decisions. The complexity of the decision making process in the treatment of acute myocardial infarction may have multiple confounders unaccounted for. Alberta is a large province with large rural catchment area where reperfusion strategy by PCI may require hours in transfer and Fibrinolytic may be chosen over PCI due to the time factor to preserve myocardium.¹¹

CONCLUSIONS

Elderly patients have more comorbidities, worst in-hospital clinical outcomes and are more likely to receive no reperfusion therapy for STEMI compared to patients < 75 years. When reperfusion is undertaken practising clinicians preferred primary PCI over fibrinolysis in both age groups. Acknowledging physician driven patient selection, outcomes appear favourable in the elderly receiving fibrinolysis. Further systematic assessment of elderly patients with STEMI is warranted.

Competing interests None declared.

Ethics approval University of Alberta HREB.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Mehta RH, Rathore SS, Radford MJ, *et al*. Acute myocardial infarction in the elderly: differences by age. *J Am Coll Cardiol* 2001;38:736–41.
2. Alexander KP, Newby LK, Armstrong PW, *et al*. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. *Circulation* 2007;115:2570–89.
3. Boucher JM, Racine N, Thanh TH, *et al*. Quebec Acute Coronary Care Working Group. Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction. *CMAJ* 2001;164:1285–90.
4. Hafiz AM, Jan MF, Mori N, *et al*. Contemporary clinical outcomes of primary percutaneous coronary intervention in elderly versus younger patients presenting with acute ST-segment elevation myocardial infarction. *J Interv Cardiol* 2011;24:357–65.
5. [No authors listed]. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. *Lancet* 1994;343:311–22.
6. Berger AK, Schulman KA, Gersh BJ, *et al*. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. *JAMA* 1999;282:341–8.
7. Berger AK, Radford MJ, Wang Y, *et al*. Thrombolytic therapy in older patients. *J Am Coll Cardiol* 2000;36:366–74.
8. Thiemann DR, Coresh J, Schulman SP, *et al*. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. *Circulation* 2000;101:2239–46.
9. Velders MA, James SK, Libungan B, *et al*. Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry. *Am Heart J* 2014;167:666–73.
10. Viana-Tejedor A, Loughlin G, Fernandez-Aviles F, *et al*. Temporal trends in the use of reperfusion therapy and outcomes in elderly patients with first ST elevation myocardial infarction. *Eur Heart J Acute Cardiovasc Care*. Published Online First: 5 Jan 2015. doi:10.1177/2048872614565928
11. Shavadia J, Ibrahim Q, Sookram S, *et al*. Bridging the gap for nonmetropolitan STEMI patients through implementation of a pharmacoinvasive reperfusion strategy. *Can J Cardiol* 2013;29:951–9.
12. Rodriguez-Leor O, Fernandez-Nofrerias E, Carrillo X, *et al*. Results of primary percutaneous coronary intervention in patients ≥ 75 years treated by the transradial approach. *Am J Cardiol* 2014;113:452–6.
13. Ielasi A, Brugaletta S, Silvestro A, *et al*. Everolimus-eluting stent versus bare-metal stent in elderly (≥ 75 years) versus non-elderly (< 75 years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the examination trial. *Int J Cardiol* 2015;179:73–8.
14. Armstrong PW, Gershlick A, Goldstein P, *et al*. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. *Am Heart J* 2010;160:30–5.
15. Deckert-Sookram J, Sookram S, Valaire S, *et al*. Evaluating clinical reason and rationale for not treating STEMI patients with reperfusion therapy: InSight from a comprehensive cohort therapy. *Can J Cardiol* 2009;25(Suppl B):133B–4B.